Zentalis reports 15.8-month median overall survival with azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer

• Zentalis Pharmaceuticals announced its first overall survival results for azenosertib from DENALI Part 1b, published in an ESMO Congress 2026 abstract.
• Survival was longer in Cyclin E1-positive platinum-resistant ovarian cancer patients than in the biomarker-negative subgroup, with no new safety signals observed.
• The abstract reported favorable survival compared with historical single-agent chemotherapy benchmarks in the biomarker-positive group, not a direct trial comparison.
• Results support further development in biomarker-selected patients through ongoing DENALI Part 2 and ASPENOVA Phase 3 confirmatory trials.
• The data will be presented at ESMO Congress in Madrid on October 23, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610181805PRIMZONEFULLFEED9847969) on October 18, 2026, and is solely responsible for the information contained therein.